Nexthera Capital LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Nexthera Capital LP
CRD #226660
SEC #801-99366
CIK #0001646343
AUM
Employees 6 (67% Investors, 0% Brokers)
Fees
Minimum
Phone646-213-7030
Address900 Third Avenue
New York, NY 10022
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
4003202401608002009201420192025
Fees and Compensation — Form ADV Part 2A (8/30/2019) [Brochure]
Item 5: Fees and Compensation

Our fees and compensation are described in the advisory contracts we enter into with our
Clients.

Any separately managed accounts that we may manage will be charged fees on a case-by-
case basis, which may include management fees and/or performance based fees.

Management Fee

For Clients who are separate accounts, the timing of management fees and/or performance
fee payments, and whether we should deduct the fees directly, is determined on a case-by-
case basis.

Incentive Allocations and Fees

Expenses borne by Clients other than the Funds are negotiated on a case-by-case basis.

Nexthera Capital LP                                                        Form ADV Part 2A
Account Minimums and Types of Clients — Form ADV Part 2A (8/30/2019) [Brochure]
Item 7: Types of Clients

Our clients currently are the separate account that we sub-advise. We may in the future
also provide advisory services to additional pooled investment vehicles and/or separately
managed accounts.
Sector Form 13F Holdings Value ($M)
Insmed Inc 12.1
Boundless Bio Inc 11.1
Neurocrine Biosciences Inc 7.8
Avi Biopharma Inc 7.6
Coherus Biosciences Inc 7.0
Ascendis Pharma A/S 6.9
Pacira Pharmaceuticals Inc 6.5
UroGen Pharma Ltd 6.4
Uniqure NV 4.7
Amarin Corp PLC UK 4.5
View All
Holdings by Sector ($M)
70056042028014002015201620182020
Type Form D Funds Date Sold AUM
HF Nexthera Capital Master Fund LP [2015-05-29] 30.8 M 206.5 M
Filed 2018-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 2 147.6
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 2 147.6
By Discretionary
Discretionary 2 147.6
Non-Discretionary 0 0.0
Total 2 147.6
By Non-United States Persons
Non-United States Persons 90.7
United States Persons 56.9
Total 2 147.6
Form D Directors Role # Filings # Firms 2011 - 2026
Ori Hershkovitz Executive Officer 4 2
Daniel Malek Executive Officer 3 2
EDGAR Form CIK 2011 - 2026
13F-HR [0001646343]
SC 13G [0001646343]
Form 13D/13G Filer Form 13D/13G Subject Filed
Nexthera Capital LP Chiasma Inc [2018-11-26]
Nexthera Capital LP Catalyst Biosciences Inc [2018-06-11]
Nexthera Capital LP Oncosec Medical Inc [2018-04-27]
Nexthera Capital LP Zosano Pharma Corp [2018-04-05]
Nexthera Capital LP Catalyst Biosciences Inc [2017-12-27]
Nexthera Capital LP Vistagen Therapeutics Inc [2016-02-29]
Firm Profile (Form ADV)
Discretionary AUM$0.2B
ServesInstitutional
Fund TypesHedge Fund
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com